SecProbe.io

CORRESP
1
filename1.htm

      January 22, 2024

      VIA EDGAR

      U.S. Securities and Exchange Commission

      Division of Corporation Finance

      100 F. Street, NE

      Washington, D.C. 20549

      Attention: Lauren Hamill

                Re:

                Ocuphire Pharma, Inc.

      Registration Statement on Form S-3

      File No. 333-276462

      Acceleration Request

              Requested Date:

              January 23, 2024

              Requested Time:

              4:30 P.M. Eastern Time

      Ladies and Gentlemen:

      Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ocuphire Pharma, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-276462) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may
        orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Emily Johns and Lauren Legner of Honigman LLP, counsel to the Company, to make
        such request on its behalf.

      Please confirm the effectiveness of the Registration Statement with Emily Johns of Honigman LLP by telephone at (616) 649-1908 or Lauren Legner of
        Honigman LLP by telephone at (313) 465-7119.

      [Signature page follows]

      ****

              Sincerely,

              Ocuphire Pharma, Inc.

              /s/ Amy Rabourn

              Amy Rabourn

              SVP of Finance

            cc:

              Emily Johns, Honigman LLP

      Lauren Legner, Honigman LLP